Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
Journal
World journal of gastroenterology
Journal Volume
28
Journal Issue
11
Date Issued
2022-03-21
Author(s)
Cheng, Chien-Yu
Lin, Chi-Ying
Yang, Chia-Jui
Lee, Nan-Yao
Liou, Bo-Huang
Tang, Hung-Jen
Liu, Yuang-Meng
Lee, Chun-Yuan
Chen, Tun-Chieh
Lee, Yuan-Ti
Lu, Po-Liang
Tsai, Hung-Chin
Wang, Ning-Chi
Hung, Tung-Che
Cheng, Shu-Hsing
Abstract
Hepatitis C virus (HCV) genotype 6 (HCV-6) infection is prevalent predominantly in Southeast Asia, and the data on the virologic response of HCV-6 to direct-acting antivirals (DAAs) are sparse in people living with human immunodeficiency virus (HIV) (PLWH).
Subjects
Antiretroviral therapy; End-of-treatment response; People who inject drugs; Sustained virologic response; Tenofovir; Viral hepatitis
SDGs
Type
journal article